Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features

Journal: Cancer Research

Published: 2020-02-15

DOI: 10.1158/0008-5472.can-19-1633

Affiliations: 15

Authors: 18

Go to article
Institutions Share
Molecular Oncology Programme, CNIO, Spain 0.29
Cordelier Research Center (CRC), France 0.17
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain 0.12
Cartes d’Identité des Tumeurs (CIT), Ligue Contre Le Cancer, France 0.06
Institute of Cancer Research (ICR), MUW, Austria 0.06
Comprehensive Cancer Center Vienna (CCC), Austria 0.06
Vienna General Hospital, Austria 0.06
San Carlos Clinical Hospital (HCSC), Spain 0.03
Faculty of Biomedical Science and Health, UEM, Spain 0.03
IMDEA Food Institute, Spain 0.03
Institut Mondor de Recherche Biomédicale (IMRB), France 0.03
AstraZeneca IMED Biotech Unit Cambridge, United Kingdom (UK) 0.03
Oxford Li Ka Shing Centre for Health Information and Discovery, United Kingdom (UK) 0.03
Institute of Biomedicine of Seville (IBiS), Spain 0.02
Department of Experimental and Health Sciences (DCEXS), UPF, Spain 0.02

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER